Drug Profile
Dexmethylphenidate controlled release - Cingulate Therapeutics
Alternative Names: CTX-1301; Dexmethylphenidate HClLatest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Cingulate Therapeutics
- Developer Bio-Images Drug Delivery; Cingulate Therapeutics
- Class Behavioural disorder therapies; Phenylacetates; Piperidines; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Dopamine uptake inhibitors; Neurokinin 1 antagonists; Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Attention-deficit hyperactivity disorder
Most Recent Events
- 11 Sep 2023 Efficacy and adverse event data from a phase III CTx-1301-022 trial in Attention deficit hyperactivity disorder released by Cingulate Therapeutics
- 14 Aug 2023 Cingulate Therapeutics plans to file an NDA to the US FDA for Attention deficit hyperactivity disorder under the Section 505(b) pathway, in second half of 04 (939646
- 14 Aug 2023 Updated efficacy and adverse event data from a phase III trial in Attention-deficit hyperactivity disorder (ADHD) released by Cingulate Therapeutics